Gaining ground: Assays for therapeutics against botulinum neurotoxin

Trends in Microbiology

Volumn 18, Issue 4, 2010, Pages 164-172

  Hakami, Ramin Mollaaghababa ^a,b,c   Ruthel, Gordon ^b   Stahl, Andrea M ^b   Bavari, Sina ^b  

^a OAK RIDGE ASSOCIATED UNIVERSITIES   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c Akimeka Technologies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; BAFILOMYCIN A1; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CONCANAMYCIN A; METHYLAMMONIUM; PEPTIDOMIMETIC AGENT; SNARE PROTEIN; SYNAPTOBREVIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

BIOLOGICAL WARFARE; BOTULISM; DRUG SCREENING; ENDOCYTOSIS; ENZYME SPECIFICITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; MASS SPECTROMETRY; MICROFLUIDICS; NEUROMUSCULAR SYNAPSE; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNAPSE VESICLE; SYNAPTOSOME;

ANIMALS; ANTITOXINS; BOTULINUM TOXINS; BOTULISM; CELL LINE; CLOSTRIDIUM BOTULINUM; DRUG DISCOVERY; HUMANS; NEUROTOXINS;

EID: 77950858619     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2010.02.001     Document Type: Review

References (67)

1. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 2004, 44:167-193.
2. Montecucco C., Molgo J. Botulinal neurotoxins: revival of an old killer. Curr. Opin. Pharmacol. 2005, 5:274-279.
3. Schantz E.J., Johnson E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 1992, 56:80-99.
4. Breidenbach M.A., Brunger A.T. New insights into clostridial neurotoxin-SNARE interactions. Trends Mol. Med. 2005, 11:377-381.
5. Wein L.M., Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9984-9989.
6. Arnon S.S., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
7. Foster K.A., et al. Botulinum neurotoxin - from laboratory to bedside. Neurotox Res. 2006, 9:133-140.
8. Dolly J.O., et al. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 2009, 9:326-335.
9. Truong D.D., Jost W.H. Botulinum toxin: clinical use. Parkinsonism Relat Disord 2006, 12:331-355.
10. Chen S., Barbieri J.T. Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9180-9184.
11. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27(Suppl 4):D33-39.
12. Horowitz B.Z. Botulinum toxin. Crit. Care Clin. 2005, 21:825-839. viii.
13. Brunger A.T., et al. Highly specific interactions between botulinum neurotoxins and synaptic vesicle proteins. Cell Mol. Life Sci. 2008, 65:2296-2306.
14. Dong M., et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell. Biol. 2003, 162:1293-1303.
15. Dong M., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
16. Rummel A., et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:359-364.
17. Bakry N., et al. Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J. Pharmacol. Exp. Ther. 1991, 258:830-836.
18. Kale R.R., et al. Synthesis of soluble multivalent glycoconjugates that target the Hc region of botulinum neurotoxin A. Bioorg. Med. Chem. Lett. 2007, 17:2459-2464.
19. Simpson L.L. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J. Pharmacol. Exp. Ther. 1983, 225:546-552.
20. Simpson L.L., et al. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J. Pharmacol. Exp. Ther. 1994, 269:256-262.
21. Keller J.E., et al. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 2004, 43:526-532.
22. Sorensen J.B. SNARE complexes prepare for membrane fusion. Trends Neurosci. 2005, 28:453-455.
23. Willis B., et al. The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew. Chem. Int. Ed. Engl. 2008, 47:8360-8379.
24. Zuniga J.E., et al. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 2008, 16:1588-1597.
25. Schmidt J.J., Stafford R.G. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity. Biochemistry 2005, 44:4067-4073.
26. Schmidt J.J., et al. Type A botulinum neurotoxin proteolytic activity: development of competitive inhibitors and implications for substrate specificity at the S1' binding subsite. FEBS Lett. 1998, 435:61-64.
27. Sukonpan C., et al. Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease. J. Pept. Res. 2004, 63:181-193.
28. Shone C., et al. The 5th International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Neurotoxins. Workshop review: assays and detection. Neurotox. Res. 2006, 9:205-216.
29. Schmidt J.J., Stafford R.G. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl. Environ. Microbiol. 2003, 69:297-303.
30. Gul N., et al. Inhibition of the protease activity of the light chain of type A botulinum neurotoxin by aqueous extract from stinging nettle (Urtica dioica) leaf. Basic Clin. Pharmacol. Toxicol. 2004, 95:215-219.
31. Adler M., et al. A capillary electrophoresis technique for evaluating botulinum neurotoxin B light chain activity. J. Protein Chem. 2003, 22:441-448.
32. Anne C., et al. Partial protection against Botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity. Chembiochem 2005, 6:1375-1380.
33. Burnett J.C., et al. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun. 2003, 310:84-93.
34. Kalandakanond S., Coffield J.A. Cleavage of intracellular substrates of botulinum toxins A, C and D in a mammalian target tissue. J. Pharmacol. Exp. Ther. 2001, 296:749-755.
35. Ferracci G., et al. Synaptic vesicle chips to assay botulinum neurotoxins. Biochem. J. 2005, 391:659-666.
36. Marconi S., et al. A protein chip membrane-capture assay for botulinum neurotoxin activity. Toxicol. Appl. Pharmacol. 2008, 233:439-446.
37. Hines H.B., et al. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B and E. Appl. Environ. Microbiol. 2008, 74:653-659.
38. Anne C., et al. High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. Anal. Biochem. 2001, 291:253-261.
39. Mangru S., et al. Integrated bioassays in microfluidic devices: botulinum toxin assays. J. Biomol. Screen. 2005, 10:788-794.
40. Dong M., et al. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14701-14706.
41. Pires-Alves M., et al. Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon 2009, 53:392-399.
42. Bagramyan K., et al. Attomolar detection of botulinum toxin type A in complex biological matrices. PLoS ONE 2008, 3:e2041.
43. Poras H., et al. Detection and quantification of botulinum neurotoxin type a by a novel rapid in vitro fluorimetric assay. Appl. Environ. Microbiol. 2009, 75:4382-4390.
44. Cheng L.W., et al. Antibody protection against botulinum neurotoxin intoxication in mice. Infect. Immun. 2009, 77:4305-4313.
45. Boyer A.E., et al. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal. Chem. 2005, 77:3916-3924.
46. Kalb S.R., et al. The use of Endopep-MS for the detection of botulinum toxins A, B, E and F in serum and stool samples. Anal. Biochem. 2006, 351:84-92.
47. Gonzalez J.E., Negulescu P.A. Intracellular detection assays for high-throughput screening. Curr. Opin. Biotechnol. 1998, 9:624-631.
48. Cai S., et al. Botulism diagnostics: from clinical symptoms to in vitro assays. Crit. Rev. Microbiol. 2007, 33:109-125.
49. Eubanks L.M., et al. Vitamin B2-mediated cellular photoinhibition of botulinum neurotoxin A. FEBS Lett. 2005, 579:5361-5364.
50. Hall Y.H., et al. Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies. J. Immunol. Methods 2004, 288:55-60.
51. Pellett S., et al. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581:4803-4808.
52. Foran P.G., et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 2003, 278:1363-1371.
53. Sheridan R.E., et al. Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon 2005, 45:377-382.
54. Stahl A.M., et al. Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J. Biomol. Screen. 2007, 12:370-377.
55. Nuss J.E., et al. Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J. Biomol. Screen. 2010, 15:42-51.
56. Fang H., et al. A yeast assay probes the interaction between botulinum neurotoxin serotype B and its SNARE substrate. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6958-6963.
57. Thyagarajan B., et al. Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin A. J. Pharmacol. Exp. Ther. 2009, 331:361-371.
58. Yoneda S., et al. Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A. Eur. J. Pharmacol. 2005, 508:223-229.
59. Roxas-Duncan V., et al. Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother. 2009, 53:3478-3486.
60. Dodd S.L., et al. Botulinum neurotoxin type A causes shifts in myosin heavy chain composition in muscle. Toxicon 2005, 46:196-203.
61. Keller J.E. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 2006, 139:629-637.
62. Straughan D. Progress in applying the Three Rs to the potency testing of Botulinum toxin type A. Altern. Lab. Anim. 2006, 34:305-313.
63. Pickett A., et al. The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon 2008, 52:455-464.
64. Hubbell W.L., et al. Identifying conformational changes with site-directed spin labeling. Nat. Struct. Biol. 2000, 7:735-739.
65. Mollaaghababa R., et al. Time-resolved site-directed spin-labeling studies of bacteriorhodopsin: loop-specific conformational changes in M. Biochemistry 2000, 39:1120-1127.
66. Steinhoff H.J., et al. Time-resolved detection of structural changes during the photocycle of spin-labeled bacteriorhodopsin. Science 1994, 266:105-107.
67. Stoevesandt O., et al. Protein microarrays: high-throughput tools for proteomics. Expert Rev. Proteomics 2009, 6:145-157.